The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
whereas ketamine, which is now a common FDA-approved, at least in the US, it's approved for the treatment of major depression, ketamine does the opposite. Ketamine seems to increase the number of receptors in the postsynaptic neuron and lead to greater levels of excitability and electrical activity within neural circuits to a given fixed amount of neurotransmitter.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.